Onconetix, Inc. Common Stock
Veridion Score
Composite trend over time
Why is ONCO moving today?
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ONCO.
ONCO insider activity
Onconetix, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $8K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | 2026-04-21 | HRT FINANCIAL LP | Insider | sell | $0.69 | 49,710 | 33,649 | $34K | SEC Form 4 |
| 2026-04-21 | 2026-04-20 | HRT FINANCIAL LP | Insider | sell | $0.75 | 94,462 | 83,359 | $71K | SEC Form 4 |
| 2026-04-21 | 2026-04-17 | HRT FINANCIAL LP | Insider | buy | $0.73 | 34,636 | 177,821 | $25K | SEC Form 4 |
| 2026-04-21 | 2026-04-16 | HRT FINANCIAL LP | Insider | sell | $0.73 | 53,867 | 143,185 | $39K | SEC Form 4 |
| 2026-04-16 | 2026-04-15 | HRT FINANCIAL LP | Insider | buy | $0.76 | 92,554 | 197,052 | $70K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 1 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moONCO contract awards, year to date.
Public federal awards linked to this ticker.
ONCO lobbying filings, year to date.
Registered lobbying filings matched to Onconetix, Inc. Common Stock.